Lek Banned from Marketing Leading Drug in Croatia
Ljubljana, 1 October - Leading Slovenian pharmaceuticals company Lek will have to stop selling its drug Amlopin, used for high blood pressure treatment, on the Croatian market. The commercial court in Zagreb has issued a temporary order forbidding Lek's subsidiary, Lek Zagreb, to import and sell Amlopin in Croatia.
The rest of this news item is available to subscribers.
The news item consists of 1.355 characters (without spaces) or 263 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.